As of 2025-09-11, the EV/EBITDA ratio of Verrica Pharmaceuticals Inc (VRCA) is -1.87. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VRCA's latest enterprise value is 70.47 mil USD. VRCA's TTM EBITDA according to its financial statements is -37.65 mil USD. Dividing these 2 quantities gives us the above VRCA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 9.4x | 7.7x |
| Forward P/E multiples | 6.7x - 15.2x | 10.9x |
| Fair Price | (31.09) - (39.86) | (39.46) |
| Upside | -715.7% - -889.3% | -881.4% |
| Date | EV/EBITDA |
| 2025-09-11 | -1.88 |
| 2025-09-10 | -1.87 |
| 2025-09-09 | -1.86 |
| 2025-09-08 | -1.87 |
| 2025-09-05 | -1.89 |
| 2025-09-04 | -1.90 |
| 2025-09-03 | -1.92 |
| 2025-09-02 | -1.95 |
| 2025-08-29 | -2.01 |
| 2025-08-28 | -2.00 |
| 2025-08-27 | -2.02 |
| 2025-08-26 | -2.10 |
| 2025-08-25 | -2.11 |
| 2025-08-22 | -1.98 |
| 2025-08-21 | -2.04 |
| 2025-08-20 | -2.00 |
| 2025-08-19 | -2.12 |
| 2025-08-18 | -2.15 |
| 2025-08-15 | -2.10 |
| 2025-08-14 | -2.15 |
| 2025-08-13 | -2.26 |
| 2025-08-12 | -2.32 |
| 2025-08-11 | -2.29 |
| 2025-08-08 | -2.20 |
| 2025-08-07 | -2.14 |
| 2025-08-06 | -2.14 |
| 2025-08-05 | -2.01 |
| 2025-08-04 | -2.00 |
| 2025-08-01 | -2.02 |
| 2025-07-31 | -2.02 |
| 2025-07-30 | -2.11 |
| 2025-07-29 | -2.17 |
| 2025-07-28 | -2.31 |
| 2025-07-25 | -2.26 |
| 2025-07-24 | -2.36 |
| 2025-07-23 | -2.37 |
| 2025-07-22 | -2.42 |
| 2025-07-21 | -2.53 |
| 2025-07-18 | -2.65 |
| 2025-07-17 | -2.75 |
| 2025-07-16 | -2.71 |
| 2025-07-15 | -2.61 |
| 2025-07-14 | -2.65 |
| 2025-07-11 | -2.63 |
| 2025-07-10 | -2.79 |
| 2025-07-09 | -2.66 |
| 2025-07-08 | -2.77 |
| 2025-07-07 | -2.69 |
| 2025-07-03 | -2.38 |
| 2025-07-02 | -2.23 |